


PSJ15 Exh 33

CARESAlliance | Improving the Safety
of Opioid Therapy

Opioid Clinical Management Guide

A Resource for Responsible
Opioid Prescribing and Use



CARESAlliance™

Collaborating & Acting Responsibly to Ensure Safety

CARES Alliance

CARES Alliance is committed to providing education and resources to healthcare professionals and patients about medication risks, responsible prescribing, and safe use.

Safe and effective therapy for the management of chronic noncancer pain requires clinical skills and knowledge of the principles of good opioid prescribing and the assessment and management of risks associated with opioids.¹

These risks include:

- **Misuse**—use of a medication prescribed for a legitimate medical purpose other than as directed or indicated²
- **Abuse**—use of a medication for a nonmedical purpose such as altering one's state of consciousness (eg, getting high)²
- **Addiction**—a neurobiologic disease characterized by impaired control over drug use, compulsive use, continued use despite harm, and craving³
- **Overdose**—use of larger quantities of an opioid medication than can be physically tolerated, resulting in serious and sometimes fatal toxic reactions, including central nervous system and respiratory depression. Opioid overdose can be manifested by respiratory depression and extreme somnolence⁴⁻⁸ (see Glossary of Terms, p. 33, for a more complete definition).
- **Diversion**—the intentional transfer of a controlled substance from legitimate distribution and dispensing channels²

This Clinical Management Guide summarizes years of experience by leading pain management and addiction medicine specialists and guidance from leading healthcare organizations.

Content was derived from the following sources:

Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. *J Pain*. 2009;10(2):113-130.

Federation of State Medical Boards of the United States, Inc. Model policy for the use of controlled substances for the treatment of pain. http://www.fsmb.org/pdf/2004_grpol_Controlled_Substances.pdf. Accessed February 1, 2010.

Fishman SM. *Responsible Opioid Prescribing. A Physician's Guide*. Washington, DC: Waterford Life Sciences; 2007.

The information provided in this guide should help you optimize the effectiveness of opioid analgesics and thereby improve patient outcomes in your clinical practice by:

- Understanding the risks and potential adverse events associated with opioids
- Performing careful and appropriate patient selection and evaluation, and structuring of opioid therapy to accommodate increased risk
- Appropriately initiating and titrating chronic opioid therapy
- Counseling patients on the risks and benefits of opioid therapy as well as on safe use and handling, including proper disposal
- Performing regular and comprehensive patient monitoring

Guideline Spotlight

Throughout this document the American Pain Society and American Academy of Pain Medicine (APS/AAPM) Clinical Guidelines are highlighted for the reader

Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. *J Pain*. 2009;10(2):113-130.

Table of Contents

Introduction	4
Misuse and Abuse in Patients With Pain	5
Abuse of Prescription Opioids by Non-patients.....	7
Addiction	8
Overdose	9
Adverse Events	10
Selecting Appropriate Patients for Opioid Therapy.....	11
Treatment Plan and Agreement.....	15
Initiating Opioid Therapy	17
Patient Counseling	21
Periodic Patient Evaluation/Monitoring.....	23
Consultation and Referral	26
Patients at High Risk	27
Opioid Rotation	28
Exit Strategy	29
Discontinuation.....	29
Documentation	30
Understanding Applicable Laws, Policies, and Guidelines.....	31
Summary.....	32
Glossary of Terms	33
References	34

Introduction

The use of opioid analgesics for the treatment of chronic noncancer pain has increased steadily since 1980.^{9, 10} Opioids are now recognized as effective therapy for select patients when prescribed judiciously and appropriately by healthcare professionals (HCPs) who are knowledgeable about and skilled in assessing and managing the potential associated risks, including misuse, abuse, addiction, overdose, and diversion.² HCPs will encounter these risks in clinical practice when they prescribe opioids for their patients with chronic noncancer pain.

Optimizing the effectiveness of opioid analgesics in clinical practice requires HCPs to:

- Properly select patients for opioid therapy by evaluating the benefits and risks²
- Stratify patients according to their individual risk profile for opioid misuse, abuse, and addiction²
- Counsel patients on the potential benefits and risks of opioid therapy²
- Gain informed patient consent to opioid therapy with full knowledge of treatment goals, expectations, potential risks, and treatment alternatives²
- Define HCP and patient responsibilities and expectations using a written opioid use agreement²
- Monitor patients periodically and as warranted, including the use of urine drug screening (UDS) to confirm adherence to the prescribed opioid treatment plan²
- Manage patients who are at high risk for or who are currently engaging in aberrant drug-related behaviors²
- Collaborate with or refer patients to specialists such as mental health or addiction specialists when needed²

Misuse and Abuse in Patients With Pain

Patients have a right to proper, respectful, informed, and nondiscriminatory pain management and care.¹¹ However, all patients treated with opioids should be carefully monitored for signs of abuse and addiction. HCPs should also be aware that abuse of prescription opioids comes primarily through legitimate prescriptions from a single prescriber. Prescription opioids may be misused or abused by the patients to whom they are prescribed for legitimate medical purposes and by others who obtain them from these patients.¹²

Nearly 1 in 5 patients (18%) who abuse prescription opioids obtain them from a legitimate prescription from a single doctor.¹² Furthermore, estimates of primary-care patients with pain engaging in aberrant behaviors or with a positive UDS for illicit substances such as cocaine or marijuana range from 10% to 40%.¹³

Risk Factors for Abuse

HCPs should be aware of and screen for individual risk factors for abuse, including:

- Personal or family history of substance abuse¹⁴
- History of preadolescent sexual abuse¹⁴
- Mental disease/pathology¹⁴
- Social patterns of drug use¹⁴
- Psychological stress¹⁵

The primary risk factor for misuse is uncontrolled or inadequately treated pain.¹⁶

Why Patients Misuse or Abuse Prescription Opioids

Patients with pain who abuse prescription opioids identify the following reasons for their misuse or abuse.¹⁵ These reasons can provide a roadmap for HCPs to proactively intervene with patient counseling and education.

- Uncontrolled pain/pseudoaddiction (drug-seeking behavior as a result of undertreatment)
- Rational misuse (intentional misuse to improve function and quality of life)
- Chemical coping (intentional misuse as a result of stress or mental disease)
- Psychosocial or emotional issues
- Psychiatric disorders
- Addiction
- Recreational use and/or use with other prescription or illicit drugs

Reduce the Risk of Misuse and Abuse


HCPs can reduce the risk of misuse and abuse by:

- Screening patients for risk of misuse, abuse, and addiction
- Stratifying treatment for risk of misuse, abuse, and addiction
- Regularly monitoring patients for changes in potential risk factors, including aberrant drug-related behaviors and results of UDS
- Encouraging patients to read the FDA-approved Medication Guide and/or other patient information that accompanies the product
- Counseling patients on safe use, handling, storage, and disposal

Abuse of Prescription Opioids by Non-patients

More than two-thirds (70%) of individuals who abuse prescription opioids obtain them from a friend or relative (Figure 1).¹² Among those who abuse prescription opioids, 88% obtain them from a friend, relative, or from a single HCP.¹²

Figure 1: Sources of Prescription Opioid Abuse



HCPs who prescribe opioid analgesics can unwittingly be at the head of the supply chain for opioid abuse and, therefore, have an opportunity to break the chain by:

- Screening patients for risk of abuse, addiction, and diversion
- Stratifying treatment for risk of abuse and addiction
- Regularly monitoring patients for changes in risk factors for abuse, addiction, and diversion, including aberrant drug-related behaviors and UDS
- Counseling patients on the risks to family, friends, and household acquaintances of opioid abuse and overdose, as well as on the importance of keeping prescription opioids secure against theft, accidental use, and proper disposal¹²

Addiction

Opioids prescribed for the treatment of chronic pain are Schedule II controlled substances that can be abused. Use of opioid analgesics carries the risk of addiction even under appropriate medical use.^{2,4-8}

Addiction is a primary, chronic, neurobiologic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations.¹⁶ Addiction is characterized by behaviors that include one or more of the following¹⁶:

- Impaired control over drug use
- Compulsive use
- Continued use despite harm
- Craving

Concern about addiction can be an impediment to opioid prescribing and use, resulting in undertreatment of pain, inadequate pain relief, unnecessary suffering, and increased healthcare costs.³ However, a study of patients with chronic pain who were treated with opioid analgesics in the primary-care setting showed that the rate of opioid use disorders was 4-fold higher than in the general population (3.8% vs 0.9%).¹³

Before prescribing opioid analgesics for chronic pain, HCPs should perform a thorough history, physical examination, and appropriate testing and assess the patient's risk for addiction² (see Risk Stratification, p. 13).

Pseudoadddiction

Some patients may exhibit aberrant behaviors, including inappropriate drug-seeking behaviors, when pain is undertreated. Unlike true addiction, however, these behaviors resolve and function and quality of life increase when pain is effectively treated.¹⁶ Even if driven by undertreatment of pain, continued aberrant behaviors, such as self-escalation of dose, may require intervention beyond increasing the dose to control pain.

Overdose

Respiratory depression is a chief hazard of opioids and may occur in patients who are not opioid tolerant or who take too high of a dose.^{2,4-8} In fact, Schedule II opioids, including hydromorphone, morphine, oxycodone, fentanyl, oxymorphone, and methadone, have the highest potential risk of fatal overdose due to respiratory depression.^{7,8}

Overdose may occur by:

- Altering the recommended administration of opioid analgesics, such as by breaking, chewing, dissolving, or crushing tablets; by snorting, injecting, or inhaling ingredients meant to be swallowed whole; or by taking a transdermal opioid orally.⁴⁻⁸ These may lead to rapid release and absorption of a potentially fatal opioid dose.⁴⁻⁶ This is especially true for extended-release opioids
- Accidental consumption by children^{4,8}
- Use by anyone for whom the specific opioid was not prescribed⁴⁻⁸
- Use of doses greater than 60 mg morphine equivalents in patients who are not opioid tolerant⁵⁻⁸
- Overestimating the initial dose when converting a patient's dose from another opioid medication⁶⁻⁸
- Titrating a patient too quickly to allow sufficient time for blood levels to reach steady state (especially when converting to methadone from other opioid analgesics)⁴⁻⁸
- Use in patients
 - With impaired respiratory function^{4,8}
 - With debilitated health^{4,8}
 - Who do not take opioids exactly as directed^{4,8}
 - Who misuse or abuse opioids^{4,8}
 - Who take opioids concomitantly with alcohol^{4,8}
 - Who take opioids with other CNS depressants^{4,8}

Adverse Events

Certain adverse events are commonly associated with opioid therapy and can, therefore, be anticipated and either treated prophylactically or managed if they occur. The most common adverse events associated with oral opioid analgesics occurring in >10% of patients are generally gastrointestinal or central nervous system (CNS)-related and include:

- Constipation^{2,5-8}
- Nausea^{2,4-8}
- Vomiting⁶⁻⁸
- Somnolence^{2,5-8}
- Asthenia, including fatigue^{7,8}
- Dizziness^{6,7}

Adverse events reported in >10% of patients for individual products include confusion⁸, dry mouth⁸, headache⁷, pruritus⁶, pyrexia⁴, and sweating⁸

In addition to understanding these risks, HCPs should ensure that patients understand them and know how to use the medication safely (see Patient Counseling, p. 21).


Guideline Spotlight

- HCPs should anticipate, identify, and treat common opioid-associated adverse events²

Selecting Appropriate Patients for Opioid Therapy

Proper patient selection is integral to responsible opioid prescribing and use.² HCPs should make a diagnosis with appropriate differential,¹⁷ including the components of an effective patient evaluation presented below. HCPs should individualize treatment for every patient using non-opioid analgesics, opioids as needed and/or combination analgesics, or chronic opioid therapy in a progressive plan of pain management (Figure 2) in keeping with the World Health Organization and the Federation of State Medical Boards guidelines.^{4-8, 18, 19}

Figure 2: World Health Organization 3-Step Analgesic Ladder



Adapted from: World Health Organization. *Cancer Pain Relief With a Guide to Opioid Availability*. 2nd ed. Geneva, Switzerland: World Health Organization; 1996.¹⁹

Guideline Spotlight

- HCPs may consider a trial of opioid therapy in patients whose pain is moderate to severe and is having an adverse impact on function or quality of life, and in whom the potential therapeutic benefits outweigh the potential harms²

Before initiating treatment, HCPs must conduct, and document in the medical record, an effective patient evaluation, including assessment of risk of substance misuse, abuse, addiction, and overdose.^{2, 18}

Components of an Effective Patient Evaluation

- Conduct a comprehensive physical examination, including appropriate diagnostic testing²
- Characterize the pain and assess its impact on the patient's ability to function and quality of life¹
- Conduct appropriate diagnostic tests to assess the underlying pain condition and determine the suitability of treatment with non-opioid therapy²
- Conduct a thorough patient history, including assessment of psychosocial factors and family history, to aid in risk stratification²
- Assess risk of abuse and addiction using patient and family history of substance abuse and validated risk assessment tools such as²:
 - Opioid Risk Tool (ORT)¹⁴
 - Screener and Opioid Assessment for Patients With Pain (SOAPP®) v1.0 and the revised SOAPP (SOAPP®-R)^{20, 21}
- Conduct a comprehensive benefit-to-harm analysis to determine the appropriateness of opioid therapy²

Structuring Therapy According to Risk (Risk Stratification)

After performing an effective patient evaluation, HCPs should structure opioid therapy to accommodate the identified risk.² Figure 3, below, presents a proposed method for stratifying patients into basic groups according to lower, moderate, and higher risk. This can be used as a practical framework to help determine which patients may be safely treated in the primary-care setting, those who should be co-treated with specialist support, and those who should be referred for management of their chronic pain condition in a specialist setting.

Figure 3: Risk Stratification

Lower Risk	Moderate Risk	Higher Risk
Primary Care Patients	Primary Care Patients With Specialist Support	Pain Specialist Patients
ORT Score: 0-3	ORT Score: 4-7	ORT Score: 8+
<ul style="list-style-type: none"> • No past or current substance use disorders • No family history of substance use disorders • No major or untreated psychopathology 	<ul style="list-style-type: none"> • May have a history of substance use disorders • May have a family history of problematic drug use • May have past or concurrent psychopathology • Not actively addicted 	<ul style="list-style-type: none"> • Active substance use disorders • Major, untreated psychopathology • Actively addicted

Overlap exists among individual risk groups.

Adapted from: Webster LR, Webster RM. *Pain Med.* 2005;6(6):432-442,¹⁴ and Gourlay DL et al. *Pain Med.* 2005;6(2):107-112.¹⁷

ORT = Opioid Risk Tool (see Figure 4).

- Patients with 4 or more aberrant behaviors or positive results of a UDS (random testing) may also be considered to be at moderate risk^{13, 15}
- Patients with positive results of a UDS from non-random screening may be considered high risk^{13, 15}

Figure 4: Opioid Risk Tool (ORT)

Opioid Risk Tool Clinician Form		
Patient's name and date of birth: _____		
Mark each box for applies:		
1. History of abuse of substances (drugs, alcohol)	Never	Always
Abuse	111	011
Alcohol/Drugs	112	012
Prescription Drugs	114	014
2. Personal History of Significant Abuse	Never	Always
Abuse	211	021
Alcohol/Drugs	212	022
Prescription Drugs	214	024
3. Age (years) - all except 17 and 45	411	041
4. History of Significant Social Problems	113	013
5. Psychiatric Disease	Never	Always
Attention Deficit Disorder, Obsessive-Compulsive Disorder, Bipolar, Schizophrenia	115	015
Depression	116	016
Scoring Totals: _____		

Not Applicable to patients of 17 years of age or older. Do not use for patients with a history of abuse of substances (drugs, alcohol) or significant social problems. Do not use for patients with a history of abuse of substances (drugs, alcohol) or significant social problems. Do not use for patients with a history of abuse of substances (drugs, alcohol) or significant social problems.

Webster LR, Webster RM. *Pain Med.* 2005;6(6):432-442.¹⁴
Available for download for free at www.caresalliance.org

Risk stratification is also useful for guiding the approach to monitoring.

- In patients at low risk for adverse outcomes who receive stable doses of opioids, monitoring once every 3 to 6 months may be sufficient²
- Patients who may need more frequent or intense monitoring include older patients or those with a history of an addictive disorder, an occupation demanding mental acuity, an unstable or dysfunctional social environment, or comorbid psychiatric or medical conditions²
- In patients at very high risk, monitoring on a weekly basis may be necessary²

Guideline Spotlight

- HCPs may consider opioid therapy for patients with chronic noncancer pain and history of drug abuse, psychiatric issues, or serious aberrant drug-related behaviors only if they are able to implement more frequent and stringent monitoring parameters²

Treatment Plan and Agreement

HCPs should inform patients about the risks and benefits associated with treatment and gain their consent before initiating a trial of opioid therapy.^{2, 18} Before prescribing opioid therapy, establish a treatment plan and an opioid use agreement.^{1, 2, 18}

The treatment agreement can enhance the patient-HCP relationship and provides an opportunity for patient education and counseling. Treatment agreements can engage patients by making them active participants in their care, clarify roles, motivate adherence, avoid misunderstandings, and establish a foundation for future decision-making.¹

- Establish and document a treatment plan that includes goals of therapy, how opioids will be prescribed and taken, and expectations for follow-up and monitoring²
- Discuss the risks of and alternatives to opioid analgesics²
- For opioid analgesics with a Medication Guide, provide the Medication Guide to patients every time the medication is dispensed, as it may contain important new information^{2, 5-8}
- Document the treatment plan, including patient and HCP responsibilities and expectations for the appropriate and safe use of opioids, in an opioid use agreement²
- Psychotherapeutic interventions including cognitive-behavioral therapy should be routinely integrated into the pain management plan²

Guideline Spotlight

- When starting chronic opioid therapy, informed consent should be obtained. A continuing discussion with the patient regarding treatment should include goals, expectations, potential risks, and alternatives to opioid therapy²
- HCPs may consider using a written management plan to document patient and clinician responsibilities and expectations and assist in patient education²

Function-Based Treatment Goals

Because it is difficult to completely relieve pain, HCPs may consider shifting from focusing on analgesia to focusing on improved functioning (eg, getting out of bed, going back to work part-time, attending more events outside the home).¹ Function-based therapy can increase patients' quality of life and reduce their burden related to pain. Function-based treatment goals should be collaborative, realistic, achievable, meaningful to the patient, and verifiable.¹ See Figure 5 for examples of verifiable functional goals.¹

Figure 5: Examples of Verifiable Functional Goals

Begin physical therapy	Letter from therapist
Walk around block	Pedometer recording
Return to work	Pay stubs
Exercise daily	Gym attendance records
Participate in support group	Letter from group

Adapted from: Fishman SM. *Responsible Opioid Prescribing*. A Physician's Guide. Washington, DC: Waterford Life Sciences; 2007.¹

Initiating Opioid Therapy

Initiation of opioid therapy should be viewed as a short-term trial with a duration of several weeks to several months to determine appropriateness.²

Individualize Treatment

Selection of the opioid to be prescribed, initial dosing, and titration should be individualized based on each patient's:

- Health status²
- Prior opioid exposure^{2*}
- Attainment of therapeutic goals²
- Predicted or observed harms²

*Many opioid analgesics, and high doses of most opioid analgesics, should be prescribed only for patients who are already opioid tolerant.⁵⁻⁸

In the selection of the initial opioid dose, give attention to the following^{2, 4-8, 18, 22}:

- The type and severity of the patient's pain
- The daily dose, potency, and specific characteristics of the opioid the patient has been taking previously
- The reliability of the relative potency estimate used to calculate the equivalent opioid dose needed
- The patient's risk factors for overdose, including:
 - Degree of opioid tolerance
 - Age, general condition, and medical status
 - Concurrent use of non-opioid analgesics and other medications, such as those with CNS activity
- The patient's risk factors for misuse, abuse, addiction, or diversion, including a prior history of abuse, addiction, or diversion
- The balance between the risks and benefits

Special Cautions for Methadone: Conversion, Initiation, and Titration

A number of epidemiologic studies suggest an increased rate of methadone-associated deaths in the United States²³⁻²⁵

Methadone is characterized by complicated and variable pharmacokinetics and pharmacodynamics and should be initiated and titrated cautiously by clinicians familiar with its use and risks.²

- Because of its very long and variable half-life, methadone must be titrated carefully to avoid the potential for delayed adverse events such as overdose²
- Although the half-life of methadone is usually estimated at 15-60 hours, a half-life as high as 120 hours has been reported²
- In a patient for whom the methadone half-life is 60 hours, it would take almost 12 days on a stable dose of methadone to approach a steady state²
- The equianalgesic ratio between methadone and other opioid agonists may vary widely as a function of previous dose exposure^{4,7}
- Deaths, cardiac arrest and respiratory depression, have been reported during initiation and conversion of pain patients to methadone treatment from treatment with other opioid agonists²⁶
- Patients tolerant to other opioids may not be completely tolerant to methadone²⁶
- Deaths have occurred in opioid-tolerant patients during conversion to methadone²⁶
- Methadone should be started at low doses and titrated slowly, and increases should occur no more frequently than weekly²
- Particular vigilance is necessary during treatment initiation, conversion from an opioid to methadone, and titration²
- It is extremely important to monitor all patients closely when converting from methadone to other opioid agonists^{4,7}
- Methadone should not be used to treat breakthrough pain²

Find the Equianalgesic Dose

A recent Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation recommended utilization of published equianalgesic dose tables when converting a dose from a patient's existing opioid therapy.²²

These equianalgesic dose tables can be found in the prescribing information for each product (see Knotkova et al²⁷ for an evidence-based review of the current equianalgesic dose tables). It should be noted that these tables are based on mean data. There are large individual differences in actual equianalgesic responses. Therefore, these tables should only be used as a general guide; conversion must be individualized using clinical judgment. Because of several limitations of these conversion ratios, the panel also recommended additional dose adjustments after calculation of the equianalgesic dose to determine the approximate starting dose.^{22, 27}

Determine the Approximate Starting Dose

To reduce the risk of unintended overdose, adjust the calculated conversion ratio based on a clinical assessment of risk.²²

- Calculate an automatic safety factor
 - 25%–50% reduction in the equianalgesic dose for most oral opioids
 - 75%–90% reduction in the equianalgesic dose for patients switching to methadone
 - Adjustment not required when converting from oral or parenteral opioids to transdermal fentanyl
 - Initiate at the lowest available dose regardless of previous opioid regimen when converting to oral transmucosal fentanyl citrate
- Calculate an additional dose adjustment based on assessment of patient characteristics, including:
 - Pain severity at the time of conversion
 - Existence of other medical or psychosocial factors that potentially alter potency or the likelihood that the initial dose will be analgesic, relatively free of adverse effects, and unlikely to precipitate withdrawal
- HCPs should refer to the product labeling for additional information concerning risks and safe use

Titrate Opioid Therapy

It is important to titrate therapy for each patient individually for optimal analgesia with minimal adverse effects. HCPs should have a strategy to frequently assess the patient's initial response to opioid treatment and titrate to optimize outcomes²²—that is, to the dose that provides adequate pain relief with tolerable adverse effects. Titration should take into account the time required for the new opioid to reach steady state, which may range from 24–36 hours to 6 days (Table 1).^{4,8}

- Titrate to adequate pain relief with tolerable adverse effects
- Consider dose increases of 25%–50%
- Titrate no more frequently than it takes to reach steady state
- Assess pain relief and adverse reactions frequently
- Manage breakthrough pain and adverse reactions, such as constipation
- Consider dose increase of the around-the-clock therapy if more than 2 medications per day for 2 consecutive days are needed for breakthrough pain

Table 1: Time to Steady State of Select Long-Acting Opioids^{2, 4-8, 22, 26}

Opioid Analgesic	Time to Steady State
Oxycodone ER	1–1.5 days
Morphine and Naltrexone ER	2+ days*
Oxymorphone ER	3 days
Hydromorphone ER	3–4 days
Methadone	3–12+ days**
Fentanyl transdermal system	6 days

*Dose-related.

**See Special Cautions for Methadone, p. 18.

Patient Counseling

Before initiating treatment with opioid analgesics, counsel patients and caregivers on opioid risks and safe use.^{2, 4-8}

Instruct patients to read the Medication Guide or Patient Labeling each time their opioid analgesic is dispensed because new information may be available.^{2, 4-8}

Topics to discuss with patients before initiating opioid therapy include:

• Risks

- Potential for serious risks, including misuse, abuse, addiction, and overdose²
- Potential risk of fatal overdose to anyone for whom the medication was not specifically prescribed (especially children)
- Potential for common opioid-related adverse effects, such as constipation, nausea, and sedation²

• Safe Use

- Certain opioids and high doses of most opioids are only for patients who are already receiving opioid pain medicine and whose bodies are used to taking these medications⁵⁻⁸
- Opioid analgesics must be taken only as directed⁴⁻⁸
- Oral tablets designed to be swallowed whole should never be broken, chewed, dissolved, or crushed; the ingredients should not be snorted, injected, or inhaled; and transdermal opioids should not be taken orally, as doing so may result in a fatal overdose⁴⁻⁸
- The opioid dose should not be changed without first consulting an HCP^{2, 4-8, 22}
- Opioids should not be taken with alcohol or other medications that cause CNS or respiratory depression⁴⁻⁸

- **Safe Handling**

- Opioid analgesics should be kept in a secure place out of the reach of anyone for whom they are not prescribed, especially children^{2, 4-8}
- Opioid analgesics should only be taken by the individuals for whom and for the conditions for which they have been prescribed⁴⁻⁸
- Opioid analgesics are subject to misuse, abuse, addiction, overdose, and diversion, and therefore should be carefully stored to prevent theft and disposed of when no longer needed^{4-8, 18}
- It is against the law to sell or give away opioid medication^{4-8, 18}
- 70% of individuals aged 12 years and older who abuse prescription opioids obtain them from a friend or relative¹²

Guideline Spotlight

- HCPs should counsel women of childbearing potential about the risks and benefits of chronic opioid therapy during pregnancy and after delivery and should discourage use of chronic opioids during pregnancy unless the potential benefits outweigh risks²
- HCPs should counsel patients receiving chronic opioid therapy about transient or lasting cognitive impairment that may affect driving and work safety²

Periodic Patient Evaluation/Monitoring

During chronic opioid therapy, patients should be periodically re-evaluated to confirm the continued need for around-the-clock opioid therapy, as well as the appropriateness of current therapy based on pain control and adverse events.^{2,4-8,16,22} Patients should also continue to be monitored for clinical risk of opioid abuse, addiction, or diversion, particularly with high-dose formulations.⁴⁻⁸ Periodic reviews, like opioid treatment itself, should be individualized for each patient and guided by the HCP's own judgment.¹

Clinicians should routinely carry out a thorough clinical assessment for presence of aberrant drug-related behaviors, substance use, and psychological issues. One tool (Figure 6) to aid in monitoring patients during the course of opioid therapy includes the 4 A's of outcome assessment.

- Analgesia (sustained efficacy)
 - Pain must be monitored and documented at baseline and at all subsequent office visits using a validated scale for rating pain intensity²⁸
- Activities of daily living (functional status)
 - Progress toward achieving therapeutic goals, including improvement in activities of daily living and psychosocial functioning, should be documented at each office visit²⁸
- Adverse effects*
 - Optimal pain relief with minimal adverse effects is the goal of pain management; HCPs should monitor and manage opioid-associated adverse effects throughout treatment²⁸
- Aberrant drug-related behaviors
 - Aberrant behaviors indicative of misuse, abuse, and addiction may arise in patients receiving long-term opioid therapy and therefore should be assessed at every office visit and addressed if present²⁸

*Adverse event information may be reported to the FDA MedWatch Reporting System by phone at 1-800-FDA-1088 (1-800-332-1088) or by mail using Form 3500 at www.fda.gov/medwatch.



In addition to patient self-reporting, other monitoring tools to verify adherence to the therapeutic plan include:

- Urine drug screening (UDS)
 - ~ Routine UDS in all patients receiving opioid therapy can effectively detect the presence of nonprescribed or illicit substances or the lack of prescribed substances that would not be revealed by patient self-reporting alone²
- Pill counts
 - ~ Pill or tablet counts can be used to verify adherence to the prescribed dosing regimen²
- Family member or caregiver interviews²
- Prescription monitoring program data²

Guideline Spotlight

- HCPs should periodically obtain a UDS from all patients to confirm adherence to the opioid treatment plan, regardless of whether a patient is at high risk for, or has engaged in, aberrant drug-related behaviors²

Continuing Opioid Therapy

The decision to continue opioid therapy after the initial trial should be based on several key outcomes²:

- Progress in meeting defined therapeutic goals
- Presence and severity of adverse effects
- Change in underlying pain condition
- Change in psychiatric or medical comorbidities
- Identification of aberrant drug-related behavior, addiction, or diversion

Consultation and Referral

Patients with chronic noncancer pain have more comorbidities and are in greater need of healthcare services than other patients.² This complexity can present a clinical challenge for HCPs, who may find that some of their patients' needs fall outside their area of expertise.¹ When such circumstances arise, HCPs should refer patients to clinicians who possess the specialized skills required.^{1, 18} HCPs should coordinate patient consultation with, and facilitate communication between, these other HCPs as needed.²

Guideline Spotlight

- HCPs should evaluate patients engaging in aberrant drug-related behaviors for appropriateness of opioid therapy or need for restructuring of therapy, referral for assistance in management, or discontinuation of opioid therapy²
- HCPs should pursue consultation, including interdisciplinary pain management, when patients with chronic noncancer pain may benefit from additional skills or resources the HCPs cannot provide²

Tips for Facilitating the Referral Process

- Do not delay in referring patients¹
- Provide the information the consultant will need to evaluate the patient¹
- Make the referral as specific as possible by explaining just how the consultant can help you and your patient¹
- Maintain a current list of colleagues who may serve as consultants when the need arises¹
- Have a "go-to" pain specialist and addiction specialist to whom you can refer patients at the ready¹
- Communicate with consultants so you know what they are doing to help your patient¹

Patients at High Risk

Patients who have a history of drug abuse and/or are at high risk for aberrant drug-related behaviors do experience chronic noncancer pain, and these patients are entitled to effective pain management.^{2, 17, 18} It is recognized, however, that prescribing opioids to patients who are at high risk poses a clinical challenge.²

Tips to help balance the risk-benefit profile in such patients include the following^{1, 2}:

- More frequent and intense monitoring
- Authorization of limited prescription quantities
- Consultation or co-treatment with specialists in addiction medicine and/or mental health
- Re-evaluation and possible restructuring of therapy
- Temporary or permanent tapering of opioid doses
- Addition of psychological therapy or other non-opioid treatment
- Structured opioid agonist therapy with methadone or buprenorphine
- Possible referral for opioid detoxification and withdrawal management
- Discontinuation of treatment in patients known to be diverting opioids or engaging in seriously aberrant behaviors (eg, injecting oral formulations)


Guideline Spotlight

- When repeated dose escalations occur, HCPs should evaluate potential causes and reassess benefits relative to harms²
- In patients who require relatively high doses of chronic opioid therapy, HCPs should evaluate for unique opioid-related adverse effects, changes in health status, and adherence to the opioid use agreement on an ongoing basis and should consider more frequent follow-up visits²
- HCPs should taper or wean patients off chronic opioid therapy if they engage in repeated aberrant drug-related behaviors or drug abuse/diversion, experience no progress toward meeting therapeutic goals, or experience intolerable adverse effects²

Opioid Rotation

Opioid rotation, or a switch in the existing opioid therapy, involves changing an opioid analgesic or route of administration with the goal of improving patient outcomes.²² Given the individual differences in patient response to different opioids, opioid rotation is a common clinical practice (Figure 7).^{30, 31}

Figure 7: Cumulative Percentage of Patients Achieving an Effective Opioid Dose with Opioid Rotation



Adapted from: Quang-Cantagrel ND et al. *Anesth Analg*. 2000;90(4):933-937.³¹

Indications for opioid rotation include²²:

- Occurrence of intolerable adverse effects
- Poor analgesic efficacy despite aggressive dose titration
- Problematic drug-drug interactions
- Preference or need for a different route of administration
- Change in clinical status (eg, concern about drug abuse) or clinical setting that suggests benefit from another opioid
- Financial or drug-availability considerations

Guideline Spotlight

- HCPs should consider opioid rotation when patients experience intolerable adverse effects or inadequate benefit despite dose increases²

Exit Strategy

Termination of opioid therapy, rather than opioid rotation, should be considered under certain circumstances. When a patient is involved in illegal activity, such as selling prescriptions or forging signatures to obtain prescriptions, opioid therapy for that patient should be terminated immediately. Termination should also be considered for patients with opioid addiction who refuse treatment for their addiction.¹ Some states may have specific legal or regulatory requirements for termination.

When terminating a patient from opioid therapy:

- Meet with the patient and caregiver/family member to review the exit criteria in the treatment agreement and inform them of the reason for termination
- Clarify that termination is for the patient's benefit
- Clarify that pain management is not being abandoned
- Provide a list of names of other HCPs in the area or tell the patient to contact the local medical society to aid them in obtaining a list of HCPs
- Explain the effect of temporarily heightened pain to the patient
- Implement non-opioid pain strategies, such as psychiatric or behavioral therapy; physical therapy; non-opioid analgesics; treatment for insomnia, anxiety, or depression; and interventional procedures
- Refer patients with apparent addiction for evaluation and addiction management
- Counsel patients on proper medication disposal
- Refer to each product's full Prescribing Information and Medication Guide or Patient Labeling for guidance

Discontinuation

In general, treatment with opioid analgesics should not be abruptly discontinued.⁴⁻⁸ Safe discontinuation of opioid therapy requires gradual tapering of the opioid dose to prevent signs and symptoms of opioid withdrawal in physically dependent patients.¹

Documentation

The Federation of State Medical Boards expects HCPs to incorporate safeguards into their practices to minimize the potential for abuse and diversion.¹⁶ All opioid prescribing should be based on clear documentation of unrelieved pain.¹⁸

Records should be kept current and accessible at all times and should include^{1, 18}:

- More frequent and intense monitoring
- Results of diagnostic, therapeutic, and laboratory tests
- Evaluations and consultations
- Treatment objectives and goals
- Discussion of treatment risks and benefits
- Treatments
- Medications (including date, type, dosage, and quantity prescribed)
- Instructions and agreements
- Periodic reviews

Tools that can aid in the documentation of opioid therapy include:

- Informed consent and opioid use agreements¹
- The ORT, SOAPP®, and SOAPP®-R tools to assess the potential for opioid abuse^{14, 20, 21}
- UDS to monitor patient adherence to opioid therapy²
- The PADT™ to assess treatment progress²⁸
- The Current Opioid Misuse Measure (COMM™) tool to measure aberrant medication-related behaviors³²

These tools are available through **www.caresalliance.org**.

Understanding Applicable Laws, Policies, and Guidelines

Policies and laws that guide the treatment of chronic pain and are designed to enhance pain management are frequently updated and, therefore, should be reviewed by HCPs regularly.¹ The goals of these laws, policies, and guidelines are to achieve a rational balance between a patient's right to effective pain management and society's need to be protected from drug abuse.¹ Information on applicable laws guiding opioid prescribing and use can be accessed via the Federation of State Medical Boards Web site (www.fsmb.org).^{1, 18}

HCPs who prescribe opioids must also be familiar with the Federal Controlled Substances Act (CSA), which gives authority to HCPs to prescribe, dispense, and administer controlled substances for legitimate medical purposes in the course of professional medicine.¹ The CSA also seeks to prevent diversion of controlled substances by controlling manufacturing and distribution, requiring documentation, and defining penalties for violation.¹ In addition, many states have established prescription monitoring programs to further address the problems of opioid diversion and abuse.¹

Guideline Spotlight

- HCPs should be aware of current federal and state laws, regulatory guidelines, and policy statements that govern the medical use of chronic opioid therapy for chronic noncancer pain²

Summary

Opioid analgesics are a vital component of an effective strategy for the management of chronic noncancer pain. However, opioid analgesics are not appropriate for all patients. Awareness of the potential for misuse, abuse, addiction, overdose, and diversion is a responsibility of the HCP and the patient. HCPs who prescribe opioid analgesics must balance the risks of opioid therapy with the potential therapeutic benefits of these agents and be knowledgeable in assessing and managing the risks associated with opioid therapy. With such knowledge, and by consistently and routinely employing responsible opioid prescribing and management practices, HCPs can mitigate the risks and optimize the benefits of opioid analgesics to improve outcomes for their patients with chronic pain.

For additional information on responsible opioid prescribing and safe use, please consult the following complimentary CARES Alliance resources:

- Urine Drug Testing Brochure
- Opioid Clinical Management Education Module
- Validated Pain and Risk Assessment Tools, including:
 - Brief Pain Inventory (BPI)
 - Opioid Risk Tool (ORT)
 - Numeric Rating Scale (NRS)
 - Pain Assessment and Documentation Tool (PADT™)
 - and Wong-Baker Faces Pain Rating Scale
- Opioid Safe Use and Handling Guide for Patients
- Patient-Prescriber Expectations and Responsibilities Form
- CARES Alliance Web site (www.caresalliance.org)
- How to Talk to Your Doctor Brochure for Patients
- Opioid Prescribing Toolkit
- Methadone for Chronic Pain Series
 - Necessary Information for Patients
 - Necessary Information for Prescribers

Glossary of Terms

Aberrant drug-related behavior: A behavior outside the boundaries of the treatment plan, which should be established and agreed upon as early as possible in the HCP-patient relationship.²

Abuse: Any use of an illegal drug, or the intentional self-administration of a medication for a nonmedical purpose, such as altering one's state of consciousness (eg, getting high).²

Addiction: A primary, chronic, neurobiologic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving.³

Chronic opioid therapy: Daily or near-daily use of opioids for at least 90 days, often indefinitely.²

Diversion: The intentional transfer of a controlled substance from legitimate distribution and dispensing channels.²

Doctor shopping: Visiting multiple doctors to obtain additional prescriptions.

Drug-seeking behavior: Tactics include emergency calls or visits near the end of office hours; refusal to undergo appropriate examination, testing, or referral; repeated claims of loss of prescriptions; tampering with prescriptions; and reluctance to provide prior medical records or contact information for other treating physician(s).

Misuse: Use of a medication for a medical purpose other than as directed or as indicated, whether willful or unintentional, and whether harm results or not.²

Overdose: Use of larger quantities of a medication than can be physically tolerated, resulting in serious, often harmful, and sometimes fatal toxic reactions, including central nervous system and respiratory depression. Overdose can be manifested by respiratory depression, extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and sometimes pulmonary edema, bradycardia, hypotension, and death.⁴⁻⁶

Physical dependence: A state of adaptation that is manifested by an opioid-specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug, and/or administration of an antagonist.¹

Pseudoaddiction: Drug-seeking behavior that appears similar to addiction but is due to a need for more medication to control pain rather than psychological dependence on a drug.^{1, 16}

Tolerance: A state of adaptation in which exposure to a drug induces changes that result in a diminution of one or more opioid effects over time.¹

References

1. Fishman SM. *Responsible Opioid Prescribing. A Physician's Guide*. Washington, DC: Waterford Life Sciences; 2007.
2. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. *J Pain*. 2009;10(2):113-130.
3. The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society. *Clin J Pain*. 1997;13(1):6-8.
4. OPANA ER [package insert]. Chadds Ford, PA: Endo Pharmaceuticals Inc.; 2010.
5. EMBEDA [package insert]. Bristol, TN: King Pharmaceuticals, Inc.; 2009.
6. OxyContin [package insert]. Stamford, CT: Purdue Pharma LP; 2009.
7. EXALGO [package insert]. Hazelwood, MO: Mallinckrodt Inc.; 2010.
8. Duragesic [package insert]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc.; 2009.
9. Caudill-Slosberg MA, Schwartz LM, Woloshin S. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000. *Pain*. 2004;109(3):514-519.
10. Olsen Y, Daurmit GL, Ford DE. Opioid prescriptions by US primary care physicians from 1992 to 2001. *J Pain*. 2006;7(4):225-235.
11. National Pain Foundation. Pain patient bill of rights. <http://www.nationalpainfoundation.org/articles/552/pain-patient-bill-of-rights>. Accessed June 18, 2010.
12. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of Findings. <http://oas.samhsa.gov/NSDUH/2k9NSDUH/2k9ResultsP.pdf>. Accessed November 10, 2010.
13. Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD. Substance use disorders in a primary care sample receiving daily opioid therapy. *J Pain*. 2007;8(7):573-582.
14. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. *Pain Med*. 2005;6(6):432-442.
15. Webster LR, Dove B. *Avoiding Opioid Abuse While Managing Pain: A Guide for Practitioners*. North Branch, MN: Sunrise River Press; 2007.
16. American Academy of Pain Medicine, American Pain Society, American Society of Addiction Medicine. Definitions related to the use of opioids for the treatment of pain. <http://www.painmed.org/pdf/definition.pdf>. Accessed May 23, 2010.
17. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. *Pain Med*. 2005;6(2):107-112.
18. Federation of State Medical Boards of the United States, Inc. Model policy for the use of controlled substances for the treatment of pain. http://www.fsmb.org/pdf/2004_grpol_Controlled_Substances.pdf. Accessed February 1, 2010.
19. World Health Organization. *Cancer Pain Relief With a Guide to Opioid Availability*. 2nd ed. Geneva, Switzerland: World Health Organization; 1996. <http://whqlibdoc.who.int/publications/9241544821.pdf>. Accessed June 18, 2010.
20. Akbik H, Butler SF, Budman SH, Fernandez K, Katz NP, Jamison RN. Validation and clinical application of the Screener and Opioid Assessment for Patients With Pain (SOAPP). *J Pain Symptom Manage*. 2006;32(3):287-293.
21. Butler SF, Fernandez K, Benoit C, Budman SH, Jamison RN. Validation of the revised Screener and Opioid Assessment for Patients With Pain (SOAPP-R). *J Pain*. 2008;9(4):360-372.
22. Fine PG, Portenoy RK; Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation. Establishing "best practices" for opioid rotation: conclusions of an expert panel. *J Pain Symptom Manage*. 2009;38(3):418-425.
23. Center for Substance Abuse Treatment. *Methadone-Associated Mortality: Report of a National Assessment*, May 8-9, 2003. Rockville, MD: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration; 2004.
24. Maxwell JC, Pullum TW, Tannert K. Deaths of clients in methadone treatment in Texas: 1994-2002. *Drug Alcohol Depend*. 2005;78(1):73-81.
25. Oregon Department of Human Services. Methadone deaths (and distribution) on the rise. CD Summary 52, 2003. <http://www.oregon.gov/DHS/ph/cdsummary/2003/ohd5214.pdf>. Accessed December 5, 2008.
26. Methadose [package insert] Hazelwood, MO: Mallinckrodt Inc.; 2007.
27. Knotkova H, Fine PG, Portenoy RK. Opioid rotation: the science and the limitations of the equianalgesic dose table. *J Pain Symptom Manage*. 2009;38(3):426-439.
28. Passik SD, Weinreb HJ. Managing chronic nonmalignant pain: overcoming obstacles to the use of opioids. *Adv Ther*. 2000;17(2):70-83.
29. Passik SD, Kirsh KL, Whitcomb L, et al. A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. *Clin Ther*. 2004;26(4):552-561.
30. Slatkin NE. Opioid switching and rotation in primary care: implementation and clinical utility. *Curr Med Res Opin*. 2009;25:2133-2150.
31. Quang-Cantagrel ND, Wallace MS, Magnuson SK. Opioid substitution to improve the effectiveness of chronic noncancer pain control: a chart review. *Anesth Analg*. 2000;90(4):933-937.
32. Butler SF, Budman SH, Fernandez KC, et al. Development and validation of the Current Opioid Misuse Measure. *Pain*. 2007;130(1-2):144-156.



To learn more about how you can help improve patient safety and reduce the risk of prescription pain medications, call us at **1-800-233-8969** or visit our Web site:

www.caresalliance.org

Sponsored by



COVIDIEN

CARES Alliance was created to help patients, healthcare professionals, nonprofit organizations and people in the pharmaceutical industry work together to improve patient safety.

Provided as an educational resource by CARES Alliance

COVIDIEN, COVIDIEN with logo and Covidien logo are U.S. and internationally registered trademarks of Covidien AG. CARES Alliance is a service mark of Mallinckrodt Inc. © 2011 Covidien. CA-012 March 2011. Printed in USA.

COVIDIEN

675 McDONNELL BLVD
HAZELWOOD, MO 63042

WWW.COVIDIEN.COM

CONFIDENTIAL—SUBJECT TO PROTECTIVE ORDER 58678